Search Results - "Dhani, N.C."

Genotype-matched treatment for patients with advanced type I epithelial ovarian cancer (EOC) by Spreafico, A, Oza, A.M, Clarke, B.A, Mackay, H.J, Shaw, P, Butler, M, Dhani, N.C, Lheureux, S, Wilson, M.K, Welch, S, Zhang, T, Yu, C, Stockley, T, Siu, L.L, Kamel-Reid, S, Bedard, P.L

“…Abstract Background Genomic alterations that activate the MAPK signaling pathway frequently occur in Type I Epithelial Ovarian Cancers (EOCs). We evaluated…”
Get full text

Impact of somatic molecular profiling on clinical trial outcomes in rare epithelial gynecologic cancer patients by Rodriguez-Freixinos, V., Lheureux, S., Mandilaras, V., Clarke, B., Dhani, N.C., Mackay, H., Butler, M.O., Wang, L., Siu, L.L., Kamel-Reid, S., Stockley, T., Bedard, P.L., Oza, A.M.

“…Conducting clinical trials in rare malignancies is challenging due to the limited number of patients and differences in biologic behavior. We investigated the…”
Get full text

806P Pilot ambulatory malignant bowel obstruction (MBO) electronic monitoring program in patients with gynecologic cancers by Madariaga Urrutia, A., Jivraj, N., Soberanis Pina, P., Somji, F., Truon, T., Melwani, S., Lovas, M., Bhat, G., Alqaisi, H.A., Gonzalez-Ochoa, E., Veneziani, A.C., Dhani, N.C., Grant, R., Bowering, V., Oza, A.M., Wang, L., Berlin, A., Lheureux, S.

Get full text

Bridging the gap between micro- and macro-scales in medical imaging with textural analysis – A biological basis for CT radiomics classifiers? by Geady, C., Keller, H., Siddiqui, I., Bilkey, J., Dhani, N.C., Jaffray, D.A.

“…•A transfer function was developed to convert classified pathology images to linear attenuation maps.•Grey-Level Co-occurrence Matrix (GLCM) texture features…”
Get full text

Risk of Acute Leukemia Post-Autologous Stem Cell Tranplant (ASCT) for Hodgkin's Lymphoma (HL) Depends on Choice of Salvage Chemotherapy and Use of Radiation by Dhani, N.C., Roberts, T., Pintilie, M., Kuruvilla, J., Franke, N., Nagy, T., Tsang, R., Keating, A., Crump, Michael

“…Background: Late treatment-related mortality (TRM) and second cancers (SC) have an important impact on the long-term outcome of patients (pts) with HL. The…”
Get full text